Literature DB >> 31853866

Bariatric Surgery in Cirrhotic Patients: Is It Safe?

Hafsa Younus1, Amit Sharma1, Rosa Miquel1, Alberto Quaglia1, Subba Rao Kanchustambam1, Kirstin A Carswell1, Ameet G Patel2.   

Abstract

INTRODUCTION: Ten percent of cirrhotic patients are known to have a high risk of postoperative complications. Ninety percent of bariatric patients suffer from non-alcoholic fatty liver disease (NAFLD), and 50% of them may develop non-alcoholic steatohepatitis (NASH) which can progress to cirrhosis. The aim of this study was to assess whether the presence of cirrhosis at the time of bariatric surgery is associated with an increased rate and severity of short- and long-term cirrhotic complications.
METHODS: A cohort of 110 bariatric patients, between May 2003 and February 2018, who had undergone liver biopsy at the time of bariatric surgery were reassessed for histological outcome and divided into two groups based on the presence (C, n = 26) or absence (NC, n = 84) of cirrhosis. The NC group consisted of NASH (n = 49), NAFLD (n = 24) and non-NAFLD (n = 11) liver histology. Medical notes were retrospectively assessed for patient characteristics, development of 30-day postoperative complications, severity of complications (Clavien-Dindo (CD) classification) and length of stay. The C group was further assessed for long-term cirrhosis-related outcomes.
RESULTS: The C group was older (52 years vs 43 years) and had lower BMI (46 kg/m2 vs 52 kg/m2) and weight (126 kg vs 145 kg) compared to the NC group (p < 0.05). The C group had significantly higher overall complication rate (10/26 vs 14/84, p < 0.05) and severity of complications (CD class ≥ III, 12% vs 7%, p < 0.05) when compared to the NC group. The length of stay was similar between the two groups (5 days vs 4 days). The C group had significant improvement in model end-stage liver disease scores (7 vs 6, p < 0.01) with median follow-up of 4.5 years (range 2-11 years). There were no long-term cirrhosis-related complications or mortality in our studied cohort (0/26).
CONCLUSION: Bariatric surgery in cirrhotic patients has a higher risk of immediate postoperative complications. Long-term cirrhosis-related complications or mortality was not increased in this small cohort. Preoperative identification of liver cirrhosis may be useful for risk stratification, optimisation and informed consent. Bariatric surgery in well-compensated cirrhotic patients may be used as an aid to improve long-term outcome.

Entities:  

Keywords:  Adults; Bariatric surgery; Cirrhosis; Complications; NAFLD

Mesh:

Year:  2020        PMID: 31853866     DOI: 10.1007/s11695-019-04214-7

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  34 in total

Review 1.  From fat to inflammation.

Authors:  Christopher Paul Day
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

2.  Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis.

Authors:  Annalisa Berzigotti; Guadalupe Garcia-Tsao; Jaime Bosch; Norman D Grace; Andrew K Burroughs; Rosa Morillas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Roberto J Groszmann
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

3.  Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention.

Authors:  Valerio Nobili; Anna Alisi; Massimiliano Raponi
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

4.  Managing complications in cirrhotic patients.

Authors:  Markus Peck-Radosavljevic; Paolo Angeli; Juan Cordoba; Oliver Farges; Dominique Valla
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

5.  Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation.

Authors:  Jing-Lin Xia; Chunsun Dai; George K Michalopoulos; Youhua Liu
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 6.  Liver morphology in morbid obesity: a literature study.

Authors:  T Andersen; C Gluud
Journal:  Int J Obes       Date:  1984

7.  Bariatric surgery in patients with liver cirrhosis.

Authors:  Hideharu Shimizu; Viet Phuong; Munique Maia; Matthew Kroh; Bipan Chand; Philip R Schauer; Stacy A Brethauer
Journal:  Surg Obes Relat Dis       Date:  2012-09-11       Impact factor: 4.734

Review 8.  The role of fatty acids in the development and progression of nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Michael J Pagliassotti
Journal:  J Nutr Biochem       Date:  2008-04-21       Impact factor: 6.048

Review 9.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

Authors:  Raj Vuppalanchi; Naga Chalasani
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

10.  Results of laparoscopic gastric bypass in patients with cirrhosis.

Authors:  Ramsey M Dallal; Samer G Mattar; Jeffrey L Lord; Andrew R Watson; Daniel R Cottam; George M Eid; Giselle Hamad; Mordecai Rabinovitz; Philip R Schauer
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

View more
  4 in total

Review 1.  Bariatric Surgery in NAFLD.

Authors:  Mahak Chauhan; Kuldeep Singh; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2022-01-04       Impact factor: 3.199

2.  Bariatric Surgery in Cirrhotic Patients: a Matched Case-Control Study.

Authors:  Nicolás Quezada; Gregorio Maturana; María Jesús Irarrázaval; Rodrigo Muñoz; Sebastián Morales; Pablo Achurra; Cristóbal Azócar; Fernando Crovari
Journal:  Obes Surg       Date:  2020-08-17       Impact factor: 4.129

Review 3.  Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.

Authors:  Sjaak Pouwels; Nasser Sakran; Yitka Graham; Angela Leal; Tadeja Pintar; Wah Yang; Radwan Kassir; Rishi Singhal; Kamal Mahawar; Dharmanand Ramnarain
Journal:  BMC Endocr Disord       Date:  2022-03-14       Impact factor: 2.763

Review 4.  Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Zobair M Younossi; Linda Henry
Journal:  JHEP Rep       Date:  2021-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.